BMY - Bristol-Myers Squibb Company

BMY

$57.89 0.19 (-0.33%)

After Hours: $57.89 +0.00 (+0.00%)

Last updated: Apr 15, 2026 23:03

52-Week Range

$57.89

$42.52 $57.89 $62.89

Fundamentals Overview

Bristol-Myers Squibb Company is near the high of its 52-week range with attractive valuation, trading relatively flat today.

Valuation attractive

P/E 16.8 PEG 0.09 P/B 6.4 P/S 2.45

Intrinsic value (DCF)

+413.5% upside vs price

Profitability

Net margin 14.6%

Risk (Beta)

0.27 — lower vol

Earnings & growth

EPS $3.46 Rev +2.3% Profit -50.7% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Buy — 75% confidence Risk: Lower Volatility — Beta 0.27. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +413.5% upside vs price · Analyst grade: A- · Sentiment improving (3 upgrades) · 3M vs Healthcare sector: +9.9%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$118.20B

P/E (TTM)

16.75

EPS (TTM)

$3.46

Dividend Yield

2.18%

52-Week Range

$42.52 - $62.89

Volume vs Avg

N/A

Beta

0.27

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indi...

Sector: Healthcare

Headquarters: US

Employees: 34,100

IPO Date: Jun 1972

Website: www.bms.com

Beta: 0.27 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A-. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 7, Equal Weight: 4, Hold: 1, Neutral: 11, Outperform: 1, Overweight: 2, Sector Perform: 2, Underweight: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $297.27; current price is $57.89. That’s a +413.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric	Value
Valuation
P/E (TTM)	16.75
DCF value (model)	$297.27 (413.5% upside)
PEG (TTM)	0.09
P/B (TTM)	6.4
P/S (TTM)	2.45
P/FCF (TTM)	9.2
Liquidity & enterprise
Current Ratio (TTM)	1.26
Quick Ratio (TTM)	1.14
Cash Ratio (TTM)	0.44
Profitability
ROE (TTM)	N/A
ROA (TTM)	N/A
Revenue growth (YoY)	N/A
Net margin (TTM)	14.63%
Gross margin (TTM)	67.65%
Operating margin (TTM)	26.34%
Debt to equity (TTM)	N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for BMY.

Analyst Sentiment at a Glance

A- Sentiment Improving

Buy 7Equal Weight 4Hold 1Neutral 11Outperform 1Overweight 2Sector Perform 2Underweight 2

3 upgrades, 1 downgrade

Price Target Consensus

Current $57.89

Median $60.00

Consensus $62.00

Low consensus $40.00

High consensus $75.00

Stock Grades (Institutions)

Institution	Action	Previous Grade	New Grade	Date
B of A Securities	maintain	Buy	Buy	2026-04-09
Cantor Fitzgerald	maintain	Neutral	Neutral	2026-04-08
Guggenheim	maintain	Buy	Buy	2026-04-08
HSBC	maintain	Hold	Hold	2026-03-17
Piper Sandler	maintain	Overweight	Overweight	2026-02-23
Wells Fargo	maintain	Equal Weight	Equal Weight	2026-02-06
Guggenheim	maintain	Buy	Buy	2026-02-06
Citigroup	maintain	Neutral	Neutral	2026-02-06
Piper Sandler	maintain	Overweight	Overweight	2026-01-28
Citigroup	maintain	Neutral	Neutral	2026-01-27
Leerink Partners	maintain	Outperform	Outperform	2026-01-13
Scotiabank	maintain	Sector Perform	Sector Perform	2026-01-09
UBS	upgrade	Neutral	Buy	2026-01-07
Citigroup	maintain	Neutral	Neutral	2026-01-07
B of A Securities	upgrade	Neutral	Buy	2025-12-15
Guggenheim	upgrade	Neutral	Buy	2025-12-12
Morgan Stanley	maintain	Underweight	Underweight	2025-12-12
Wells Fargo	maintain	Equal Weight	Equal Weight	2025-12-10
Scotiabank	maintain	Sector Perform	Sector Perform	2025-12-04
Goldman Sachs	maintain	Neutral	Neutral	2025-12-02
Citigroup	maintain	Neutral	Neutral	2025-11-17
Citigroup	maintain	Neutral	Neutral	2025-08-01
Morgan Stanley	maintain	Underweight	Underweight	2025-07-10
Wells Fargo	maintain	Equal Weight	Equal Weight	2025-04-28
Cantor Fitzgerald	maintain	Neutral	Neutral	2025-04-23
Jefferies	maintain	Buy	Buy	2025-04-23
UBS	maintain	Neutral	Neutral	2025-04-11
Goldman Sachs	downgrade	Buy	Neutral	2025-04-08
Wells Fargo	maintain	Equal Weight	Equal Weight	2025-02-07
Cantor Fitzgerald	maintain	Neutral	Neutral	2025-02-04